Medical AI startup Aesop Technology secures $3M to further expand in the US
01 Sep 2022
Preview
Source: mobihealthnews
Photo by: Helen King/Getty Images
Taiwanese medical AI startup Aesop Technology has raised $2.9 million in a fundraising round led by Taiwania Capital ahead of its Series A funding event. The round also drew the participation of Colopl Next, 500 Startups, and BE Capital.
A spin-off from Taipei Medical University, the company was established in the US in 2020 and is now currently headquartered in San Francisco. It offers two AI-powered solutions: RxPrime, a medication decision support tool, and a clinical documentation improvement tool for spotting incorrect diagnoses called DxPrime, which was launched in June this year.
WHAT IT'S FOR
Aesop says it will use its fresh funds to strengthen its technology team and further expand its presence in the US market.
THE LARGER TREND
The fundraiser comes after it launched both of its solutions on apps marketplaces Epic App Orchard and Olive Library over the past few months.
Last year, it published a paper with Harvard University which demonstrated the international transferability of its AI model for detecting medication errors in EHR systems in the US.
Tags: Aesop Technology, Taiwan, US, CDI, startup, AI, medical coding
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.